Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data

Background: Non-randomized studies have investigated multi-agent gemcitabine-based neo-adjuvant therapies (GEM-NAT) in borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC). Treatment sequencing and specific elements of neoadjuvant treatment are still under investigation. The present meta...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Giovinazzo, Francesco, Soggiu, Fiammetta, Jang, Jin-Young, Versteijne, Eva, van Tienhoven, Geertjan, van Eijck, Casper H., Han, Youngmin, Choi, Seong Ho, Kang, Chang Moo, Zalupski, Mark, Ahmad, Hasham, Yentz, Sarah, Helton, Scott, Rose, J. Bart, Takishita, Chie, Nagakawa, Yuichi, Abu Hilal, Mohammad
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7431761/
https://ncbi.nlm.nih.gov/pubmed/32850319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01112
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares